FDA approves Akebia Therapeutics' oral anemia treatment Vafseo for chronic kidney disease patients on dialysis.

The FDA has approved Akebia Therapeutics' Vafseo (vadadustat) tablets for treating anemia in adult patients with chronic kidney disease (CKD) who have been on dialysis for at least three months. Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first oral treatment for this condition, approved in 37 countries including the US. Akebia Therapeutics plans to commercialize Vafseo in the US with its partner CSL Vifor, which has an exclusive license to sell the drug to Fresenius Kidney Care dialysis centers and other third-party dialysis organizations.

March 27, 2024
10 Articles